Welcome to our dedicated page for Elcora Advanced Materials news (Ticker: $ECORF), a resource for investors and traders seeking the latest updates and insights on Elcora Advanced Materials stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Elcora Advanced Materials's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Elcora Advanced Materials's position in the market.
Elcora Advanced Materials Corp. (TSX.V: ERA | Frankfurt: ELM | OTCQB – ECORF) announced a 10-to-1 share consolidation. This move, pending TSX Venture Exchange approval, will reduce the number of outstanding shares from 170,377,013 to approximately 17,037,701. No fractional shares will be issued, with all fractions rounded down. Share prices and convertible securities will adjust proportionately. The company aims to attract more financing opportunities with this consolidation. There will be no changes to the company's name or trading symbol. Further details will be released at a later date.
Elcora Advanced Materials announces the closing of a CDN $102,750 private placement through an 8% interest bearing, unsecured, convertible promissory note maturing on September 27, 2024. The note can be converted into up to 2,055,000 common shares at a conversion price of CDN $0.05 per share. The proceeds will be used for general working capital. All securities are subject to a four-month hold period. The placement is pending final regulatory approvals.
